Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome

PURPOSE: In March 2007, a US Food and Drug Administration boxed warning was issued for erythropoietin-stimulating agents (ESAs) regarding serious adverse events, such as venous thromboembolism (VTE). We evaluated the US Food and Drug Administration’s boxed warning of ESAs used to treat chemotherapy-...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Main Authors: Bian, John, Chen, Brian, Hershman, Dawn L., Marks, Norman, Norris, LeAnn, Schulz, Richard, Bennett, Charles L.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2017
Assuntos:
ORIGINAL REPORTS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5466011/
https://ncbi.nlm.nih.gov/pubmed/28441110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.72.6273
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares